Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide vs Tirzepatide vs Placebo on Gastric Motor Functions in Obesity
NCT06801015Phase 4Active, not recruiting
- Sponsor
- Mayo Clinic
- Start
- Oct 2025
- Primary completion
- Jan 2028
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of semaglutide, tirzepatide in obesity, sponsored by Mayo Clinic. Started Oct 2025; status: active, not recruiting.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06801015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06801015.